Lakeshore Capital Group Inc. Purchases Shares of 2,360 Stryker Co. (NYSE:SYK)

Lakeshore Capital Group Inc. purchased a new position in Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,360 shares of the medical technology company's stock, valued at approximately $850,000. Stryker accounts for about 1.3% of Lakeshore Capital Group Inc.'s portfolio, making the stock its 28th biggest position.

Several other large investors have also added to or reduced their stakes in SYK. J. W. Coons Advisors LLC raised its holdings in shares of Stryker by 0.7% during the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after purchasing an additional 26 shares during the last quarter. Mascoma Wealth Management LLC raised its stake in Stryker by 22.7% during the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after buying an additional 27 shares during the last quarter. Opal Wealth Advisors LLC lifted its holdings in shares of Stryker by 1.6% during the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after buying an additional 28 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after buying an additional 28 shares during the last quarter. Finally, JFS Wealth Advisors LLC grew its holdings in shares of Stryker by 4.4% in the fourth quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock worth $247,000 after acquiring an additional 29 shares during the period. Institutional investors own 77.09% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $442.00 target price on shares of Stryker in a report on Friday, March 21st. Truist Financial raised their price objective on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a report on Monday, May 5th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Argus set a $450.00 target price on Stryker in a research report on Monday, February 3rd. Finally, BTIG Research set a $403.00 price target on Stryker and gave the company a "buy" rating in a report on Monday, April 14th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $427.30.

Stryker Price Performance

SYK traded up $1.73 during midday trading on Thursday, reaching $382.12. 840,274 shares of the company's stock were exchanged, compared to its average volume of 1,342,547. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business has a 50-day simple moving average of $368.42 and a two-hundred day simple moving average of $376.23. The firm has a market capitalization of $145.85 billion, a price-to-earnings ratio of 49.24, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company earned $2.50 EPS. As a group, research analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is presently 45.41%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 5.20% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.